Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia in an Elderly Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients.~* Age 65 years or older.~* Fibromyalgia diagnosed according to ACR 1990 criteria.~* Pain Score ≥ 10 on Gracely scale at screening and baseline assessments.~* Discontinuation of other dual-acting antidepressant medications, including duloxetine, venlafaxine, and tricyclic antidepressants for a period not less than 4.5 times the drug half-life as of the baseline evaluation.~Exclusion Criteria:~* Uncontrolled hypertension (BP ≥ 140/90) at screening or baseline evaluations.~* Baseline orthostasis (documented drop in SBP ≥ 20 mmHg or in DBP ≥ 10 mmHg within 3 minutes after standing) at screening or baseline evaluations.~* Psychosis, active suicidality, current episode of major depression or other severe psychiatric illness, or current alcohol/substance abuse or dependence as assessed by the MINI.~* Significant cardiovascular disease, including atrial fibrillation or other dysrhythmia, congestive heart failure, valvular heart disease, or QTc prolongation on baseline EKG (\> 450 msec).~* Uncontrolled narrow angle glaucoma.~* History of seizures.~* Use of MAO inhibitor drugs within the last 14 days.~* Abnormal baseline liver or renal function tests.~* Dementia or other syndrome of cognitive impairment that could interfere with the subject's ability to participate fully in the assessment protocol.~* Obstructive uropathy in males.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milnacipran (Type: EXPERIMENTAL): Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).